Biotech

Arbutus Biopharma (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced its year-end 2017 audited financial results and provided a corporate update. As quoted in the press release: “I’m excited by the progress that Arbutus is making on delivering a cure for chronic HBV using a drug combination approach,” said Dr. Mark …

Arbutus Biopharma (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced its year-end 2017 audited financial results and provided a corporate update.

As quoted in the press release:

“I’m excited by the progress that Arbutus is making on delivering a cure for chronic HBV using a drug combination approach,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “This year we plan to introduce into clinical development two new small molecule drug candidates which will put us firmly on the path to a proprietary combination therapy for HBV. In 2017, we advanced our RNAi agent, ARB-1467, to the stage of enabling a combination study with tenofovir and pegylated interferon. We begin 2018 from a strong financial position with over $200 million in cash on a proforma basis, sufficient to fund our HBV development plans well beyond 2019. This year we look forward to beginning to receive a royalty from Alnylam based on patisiran sales enabled by our LNP intellectual property estate. This asset represents a meaningful source of runway extending capital to Arbutus, as well as further validating our LNP technology in the potentially first approved RNAi therapy. We will present data on our clinical programs in 2018 as we continue to move each asset closer to inclusion in future combination studies.”

Click here to read the full press release.

MARKETS

Markets
TSX19692.92+236.21
TSXV646.04+10.63
DOW32798.40-46.73
S&P 5004118.63-11.66
NASD12368.98-21.71
ASX6993.00+47.80

COMMODITIES

Commodities
Gold1775.26+3.33
Silver20.28-0.05
Copper3.51-0.03
Palladium2183.00-14.00
Platinum914.50+4.50
Oil94.35+0.46
Heating Oil3.45+0.01
Natural Gas8.20-0.08

DOWNLOAD FREE REPORTS

×